[Follow-up of serum monoclonal gammopathy at Guadalajara Health Area].
OBJECTIVE
To study the clinical course of patients with a serum monoclonal protein at Guadalajara Health Area.


METHODS
Prospective study of 186 patients with a newly diagnosed monoclonal component. They have been collected during the years 1999 and 2000.


RESULTS
The cumulative transformation probability at 43 months was 4.99% for those patients whose monoclonal gammopathy was overlooked, and 2% at 23 months for patients with monoclonal gammopathy of undetermined significance. The cumulative probability of survival for patients with multiple myeloma was 66.7% at 21 months. The conditional mortality rate (patients/months) at 4 years due to haematological disease was 4.48 x 10(-4) for overlooked patients, 0 for diagnosed of monoclonal gammopathy of undetermined significance and 1.388 x 10(-2) for multiple myeloma diagnosed.


CONCLUSIONS
A non malignant M component must be followed up due to it could increase patients survival rate in relation with transformation in malignant disease.
Batuecas Mohedano
M
M
Laboratorio de Análisis Clínicos, Hospital Universitario de Guadalajara, Ponferrada (León). miriambatuecas@hotmail.com
Carballo Alvarez
F
F
García Menéndez
L
L
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010265:Paraproteinemias / Q000097:blood*; D011446:Prospective Studies; D013030:Spain